Bruker Announces Acquisition of Canopy Biosciences, LLC
September 11 2020 - 7:00AM
Business Wire
Strengthens Bruker in Targeted Multi-Omics
and High-Plex Biomarker Imaging Adds Innovative
ChipCytometry Tools for Multi-Dimensional Immune Profiling
Bruker Corporation (Nasdaq: BRKR) today announced the
acquisition of Canopy Biosciences, LLC, a leader in high multiplex
biomarker imaging for immunology, immuno-oncology and cell therapy.
This acquisition enhances Bruker’s offering in targeted multi-omics
and fluorescence-based imaging techniques. Bruker’s global reach,
complementary technologies and applications knowledge will help
build on Canopy’s success to date. Financial details of the
transaction were not disclosed.
“We are excited to add the multi-omics and high-content
cytometry expertise of Canopy, and its novel ChipCytometry platform
to Bruker,” said Dr. Mark R. Munch, the Bruker NANO Group
President. “Canopy has a unique set of products that enable single
cell, tissue and suspended cell-based discovery and validation in
immunology and targeted proteomics, as well as a suite of
complementary multi-omics services.”
“We are very pleased to join Bruker,” added Dr. Edward
Weinstein, the CEO of Canopy Biosciences. “Joining forces with a
leading life-science tools provider with broad geographic reach
enables us to give many more researchers access to our powerful
high-plex ChipCytometry platform, designed for accelerating basic
immunology and clinical research, as well as biopharma drug
development.”
“Canopy has built a powerful suite of multi-omics technologies,”
explained Dr. Frank Witney, Operating Partner of Ampersand Capital
Partners, the lead Canopy investor. “Joining Bruker will strengthen
and deepen this platform, enabling researchers to better answer
their scientific and translational questions with unprecedented
power and precision.”
About Bruker Corporation (Nasdaq: BRKR)
Bruker is enabling scientists to make breakthrough discoveries
and develop new applications that improve the quality of human
life. Bruker’s high-performance scientific instruments and
high-value analytical and diagnostic solutions enable scientists to
explore life and materials at molecular, cellular and microscopic
levels. In close cooperation with our customers, Bruker is enabling
innovation, improved productivity and customer success in life
science molecular research, in applied and pharma applications, in
microscopy and nanoanalysis, and in industrial applications, as
well as in cell biology, preclinical imaging, clinical phenomics
and proteomics research and clinical microbiology. For more
information, please visit: www.bruker.com.
About Canopy Biosciences, LLC
Canopy Biosciences was formed in 2016 and has rapidly built a
comprehensive portfolio of products and services for gene editing,
gene expression analysis and regulation, and bioprocessing.
Canopy’s gene editing portfolio offers easy-to-use CRISPR kits and
full-service custom cell line engineering. Canopy has also
assembled an innovative multi-omic platform for immune profiling,
including ultrasensitive DNA sequencing (RareSeq), RNAseq, gene
expression analysis, and multiplexed protein detection in cells and
tissue samples via ChipCytometry. Canopy Biosciences is
headquartered in St. Louis, Missouri, and serves researchers at
universities, research institutions and biotechnology and
pharmaceutical companies worldwide. Additional information is
available at www.canopybiosciences.com. Its subsidiary
ZELLKRAFTWERK GmbH in Leipzig, Germany, designs and manufactures
high-plex ChipCytometry platforms and complete workflows for
high-content cytometry on cells and tissues
(www.zellkraftwerk.com).
About Ampersand Capital Partners
Founded in 1988, Ampersand is a middle market private equity
firm dedicated to growth-oriented investments in the healthcare
sector. With offices in Boston and Amsterdam, Ampersand leverages
its unique blend of private equity and operating experience to
build value and drive superior long-term performance alongside its
portfolio company management teams. Ampersand has helped build
numerous market-leading companies across each of our core
healthcare sectors, including Brammer Bio, Confluent Medical,
Genewiz, Genoptix, Talecris Biotherapeutics, and Viracor-IBT
Laboratories. Additional information about Ampersand is available
at www.ampersandcapital.com.
Forward Looking Statements for Bruker Corporation
Any statements contained in this press release related to
Bruker, Canopy Biosciences, LLC and the acquisition of Canopy
Biosciences, LLC by Bruker which do not describe historical facts
may constitute forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Forward-looking
statements are often identified by qualifiers such as “expect,”
“anticipate,” “will,” and similar expressions. Any forward-looking
statements contained in this press release are based on Bruker’s
current expectations, but are subject to risks and uncertainties
that could cause actual results to differ materially from those
indicated. Forward-looking statements in this communication
include, among other things, statements about the potential
benefits of the transaction, Bruker’s plans, objectives,
expectations and intentions, and the financial condition, results
of operations and business of Bruker following the completion of
the proposed transaction. Risks and uncertainties include, among
other things, risks and uncertainties relating to the consummation
of the proposed acquisition on the proposed terms and schedule;
Bruker’s financial and operational performance following the
completion of the proposed transaction; Bruker’s ability to
successfully integrate the business and realize the strategic and
other benefits of the acquisition; the timing of when the
acquisition will be accretive to earnings; and other risk factors
identified and described in Bruker’s filings with the Securities
and Exchange Commission, including, without limitation, Bruker’s
annual report on Form 10-K for the year ended December 31, 2019 and
subsequently filed Quarterly Reports on Form 10-Q. Bruker expressly
disclaims any intent or obligation to update these forward-looking
statements other than as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200911005050/en/
Investors: Miroslava Minkova Director, Investor Relations
& Corporate Development Bruker Corporation T: +1 (978) 663-3660
x1479 E: Investor.Relations@bruker.com Media: Stephen
Hopkins Content Marketing Manager Bruker Nano Surfaces Division T:
+1 (520) 741-1044 x1022 E: steve.hopkins@bruker.com
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Apr 2023 to Apr 2024